PTCT PTC Therapeutics, Inc.

11.25
0  -1%
Previous Close 11.39
Open 11.43
Price To book 3.25
Market Cap 384.40M
Shares 34,169,000
Volume 2,546,018
Short Ratio 2.95
Av. Daily Volume 1,255,450

SEC filingsSee all SEC filings

  1. 8-K - Current report 17776412
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 17775342
  3. 8-K - Current report 17773203
  4. 8-K - Current report 17765146
  5. CT ORDER - Confidential treatment order 17755866

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial to commence in 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. PTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S.
  2. PTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : April 20, 2017
  3. ETFs with exposure to PTC Therapeutics, Inc. : April 19, 2017
  4. PTC Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTCT-US : April 19, 2017
  5. PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs
  6. Why PTC Therapeutics Dropped 25.3% in March
  7. ETFs with exposure to PTC Therapeutics, Inc. : March 27, 2017
  8. Bernie Sanders thinks this $89,000-a-year drug should be $1,000 a year
  9. U.S. lawmakers seek pricing info on PTC Therapuetics' Duchenne drug
  10. PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  11. Biotech Movers On Friday: Neurotrope Inc (NTRP) And PTC Therapeutics, Inc. (PTCT)
  12. Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought
  13. Blog Coverage PTC Therapeutics Acquires Rights for Duchenne Muscular Dystrophy Drug from Marathon for $140 Million Upfront
  14. ($$) Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny
  15. Why PTC Therapeutics, Tellurian, and B&G Foods Slumped Today
  16. PTC Therapeutics Buys Duchenne Drug for $140M
  17. Why PTC Therapeutics Stock Is Crashing Today
  18. Blasted for high price of old MD drug, Marathon sells rights
  19. Marathon Pharma sells $89,000 drug to N.J. company amid pricing criticism
  20. PTC Sticks Its Face in a Drug-Pricing Wasps' Nest

SEC Filings

  1. 8-K - Current report 17776412
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 17775342
  3. 8-K - Current report 17773203
  4. 8-K - Current report 17765146
  5. CT ORDER - Confidential treatment order 17755866
  6. 8-K - Current report 17753422
  7. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17752292
  8. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17693035
  9. 8-K - Current report 17692941
  10. 8-K - Current report 17692933